Navigation Links
Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery

GENEVA--(BUSINESS WIRE)--Jul 8, 2007 - Late-breaking Phase III clinical trial data presented today at the XXI International Society on Thrombosis and Haemostasis (ISTH) Congress demonstrate that once-daily rivaroxaban achieved superior efficacy in the prevention of venous thromboembolism (VTE) in patients undergoing knee replacement surgery in a head-to-head comparison with enoxaparin, the current standard of care. Patients in the RECORD3 (REgulation of Coagulation in major Orthopaedic surgery reducing the Risk of DVT and PE) study who were treated with rivaroxaban demonstrated a 49% relative risk reduction (RRR) (p less than 0.001) in the composite primary endpoint of deep vein thrombosis (DVT), non-fatal pulmonary embolism (PE) and all-cause mortality compared to those treated with enoxaparin. A 62% reduction of risk (p=0.01) for developing major VTE (the composite of proximal DVT, non-fatal PE and VTE-related death) - the secondary endpoint of the trial - was observed in the patients treated with rivaroxaban. Rivaroxaban also demonstrated a similarly low rate of major bleeding compared to enoxaparin (0.6% and 0.5%, respectively).

Rivaroxaban is an investigational, oral, once-daily direct Factor Xa inhibitor. It is an anticoagulant - a drug designed to prevent and treat blood clots - in advanced clinical development for the prevention and treatment of thrombosis in acute and chronic settings, enabling convenient administration in both the hospital and at home.

Rivaroxaban is being jointly developed by Johnson & Johnson Pharmaceutical Research & Development L.L.C. (J&JPRD), and Bayer HealthCare AG.

Lead RECORD3 investigator, Michael R. Lassen, MD, of Hoersholm Hospital, University of Copenhagen, Denmark, commented: "The RECORD3 results are exciting, as they indicate that rivaroxaban may better meet the needs of many patients undergoing orthopaedic surgery. It's an important step for t
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment

Post Your Comments:
(Date:11/19/2009)..., LYON, France, Nov. 19 In respo...ying dangerous and illegal medicines, Operation Pa...y INTERPOL and the World Health Organization,s Int...skforce (IMPACT) to highlight the dangers of buyin...tiative resulted in a series of arrests and the se...
(Date:11/19/2009)..., ABBOTT PARK, Ill., Nov. 19 /PRNewswire-FirstC...NYSE: ABT ) as one of its Most Admired Corporate... Deal honored Abbott as its Most Admired Dealmake...ic use of acquisitions and divestitures since Janu...eshaped its business portfolio with a focus on hig...
(Date:11/19/2009)..., NEWPORT NEWS, Va., Nov. 19 Bre...g (BSGI/MBI) has been recognized and endorsed by t...inst breast cancer: The Society of Breast Imaging ...ocieties published articles supporting the further...gy for the early detection of breast cancer. ,,...
Breaking Medicine Technology:International Operation Combats Online Supply of Counterfeit and Illegal Medicines 2The Deal Names Abbott Top Dealmaker for Second Consecutive Year 2The Deal Names Abbott Top Dealmaker for Second Consecutive Year 3Esteemed Endorsements Recognize Promising Future of Breast-Specific Gamma Imaging (BSGI) 2Esteemed Endorsements Recognize Promising Future of Breast-Specific Gamma Imaging (BSGI) 3Obese Get Higher Doses of Radiation for X Rays 50432 1Obese Get Higher Doses of Radiation for X Rays 50432 2Obese Get Higher Doses of Radiation for X Rays 50432 3Police work undermines cardiovascular health comparison to general population shows 50430 1Police work undermines cardiovascular health comparison to general population shows 50430 2Police work undermines cardiovascular health comparison to general population shows 50430 3Caregivers may benefit from adult day care 50428 1Caregivers may benefit from adult day care 50428 2
..., June 23 Canopus BioPharma, Inc.,(OTC: CBIA), is...nes,Control Council has granted approval for a Pha...rotective effect of CB1400 on the,gastrointestiona... trial is,an important step forward in the develop...itis agent., Oral and gastrointestinal (GI) mucos...
... Calif., June 23 DaVita Inc., a leading,provider ...hronic kidney,failure and disease (CKD), recently ...ommunity-based workshops that encourage CKD patien...ed decisions about their,dialysis care., (Logo: ...ALOGO ), Available in more than 40 locations thro...
Other Medicine Technology:CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck 2DaVita Strives to Improve Quality of Life and Reduce Overall Costs of Kidney Care Through Community-Based Education 2DaVita Strives to Improve Quality of Life and Reduce Overall Costs of Kidney Care Through Community-Based Education 3
(Date:11/20/2009)..., (Seattle, Washington) November 20, 2009Emergenc...ates assess an estimated 350,000 cardiac arrests e... sudden cardiac arrest survive. Better quality ca...ospital EMS providers may be associated with bette...sortium (ROC) is the largest clinical research net...
(Date:11/20/2009)... Canadian study finds more severe cases than with ...hDay News) -- Canadian researchers are reporting t...p severe cases of H1N1 flu than seasonal flu. ,... factor for admission with pandemic H1N1 influenza...r samples," wrote Dr. Upton Allen and fellow resea...
(Date:11/20/2009)..., , SPRINGFIELD, Mo., Nov. 20 /PRNewswire/...South Central Missouri regions will now have the o...reement reached Tuesday between Missouri Consolida...s. ,, The Southwest and South Central Missouri ...ton, Cedar, Christian, Dade, Dallas, Douglas, Gree...
(Date:11/20/2009)..., , NEW YORK, Nov. 20 To...nnel retailer HSN announce the launch of a capsule... and HSN.com for the holiday season. This collect...ldren,s Research Hospital,s Thanks and Giving...rogram which encourages consumers to "give thanks ...
(Date:11/20/2009)..., , NEW YORK, Nov. 20 The U...stem reform legislation which contains a 5% tax on...urposes. The American Academy of Facial Plastic a...rongly opposes the inclusion of this tax as it is ...tes. ,, If passed into law, the tax will go i...
Breaking Medicine News(10 mins):Health News:Effect of real-time CPR feedback reported at resuscitation science symposium 2Health News:Effect of real-time CPR feedback reported at resuscitation science symposium 3Health News:Missouri Consolidated Health Care Plan Provides Mercy Health Plans Option 2Health News:DKNY JEANS Launches Exclusive Collection With HSN for St. Jude Children's Research Hospital's Thanks and Giving(R) Campaign 2Health News:DKNY JEANS Launches Exclusive Collection With HSN for St. Jude Children's Research Hospital's Thanks and Giving(R) Campaign 3Health News:AAFPRS Opposes the Proposed Tax on Medical Procedures 2
...States smoking is the leading preventable cause of...oung people from smoking. A new study finds the mo...ly they are to start smoking. //The risk of diseas...roducts are banned from advertising on television,...
...r to assess the future needs of an aging populatio...early 20 years. Within 20 years, half the babies b... 70. The physical, mental and economic needs// of ...ngland, have been surveying a group of over 70 sin...
...y that diet is second only to tobacco in causing c...or 40 per cent of cancers in the developed world, ... studies may provide detailed information on what ...to a healthy weight. Decreases in physical a...
...re being used for safe and effective delivery of d...archers// at the Mayo clinic say that familiarity ...treat allergies such as hay fever. A nasal s... act quicker than the corresponding pill. Nasal sp...
..., researchers from Cancer Research Insitiute, UK s...ast cancer risk compared to those on placebo.// Th...revent breast cancer. A group of 6050 women aged 3...at increased risk of breast cancer, because they h...
...cues patients suffering potentially fatal liver co...ses of chemotherapy are given before a stem cell t...ed for cancer treatment. But chemotherapy causes f...he liver. In this trial, headed by scientist...
Other Medicine News:
Near PT Test Card/ILLUS of The Ocular Adnexa - BC2208
Near Point Diagnostic Card Set - BC11982
... to be a corrected Rosenbaum card. The known inacc...orton and Jones in 1997 and others) have been corr...he lack of standards associated with this notation...easure a patients single letter near acuity and re...
11970R Standard Reading Test
Medicine Products: